Article
Live Respiratory Syncytial Virus (RSV) Vaccine Candidate Containing Stabilized Temperature-Sensitivity Mutations Is Highly Attenuated in RSV-Seronegative Infants and Children.
The Journal of infectious diseases - 11 Apr 2018
Buchholz Ursula J, Cunningham Coleen K, Muresan Petronella, Gnanashanmugam Devasena, Sato Paul, Siberry George K, Rexroad Vivian, Valentine Megan, Perlowski Charlotte, Schappell Elizabeth, Thumar Bhagvinji, Luongo Cindy, Barr Emily, Aziz Mariam, Yogev Ram, Spector Stephen A, Collins Peter L, McFarland Elizabeth J, Karron Ruth A
Abstract excerpt
Background: Respiratory syncytial virus (RSV) is the most important viral cause of severe respiratory illness in young children and lacks a vaccine. RSV cold-passage/stabilized 2 (RSVcps2) is a modification of a previously evaluated vaccine candidate in which 2 major attenuating mutations have been stabilized against deattenuation. Methods: RSV-seronegative 6-24-month-old children received an intranasal dose of...
Topics
- Antibodies, Neutralizing
- Antibodies, Viral
- Female
- Humans
- Immunogenicity, Vaccine
- Infant
- Male
- Mutation
- Respiratory Syncytial Virus Infections